PMC:7264098 / 11009-11198
Annnotations
LitCovid-PMC-OGER-BB
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T214 | 66-74 | GO:0035376 | denotes | entry of |
| T215 | 79-84 | NCBITaxon:10239 | denotes | virus |
| T216 | 128-133 | NCBITaxon:10239 | denotes | viral |
| T217 | 134-141 | SO:0000704 | denotes | genetic |
| T218 | 160-166 | UBERON:0002405;GO:0006955 | denotes | immune |
| T219 | 167-175 | GO:0006955 | denotes | response |
| T45166 | 66-74 | GO:0035376 | denotes | entry of |
| T6847 | 79-84 | NCBITaxon:10239 | denotes | virus |
| T60882 | 128-133 | NCBITaxon:10239 | denotes | viral |
| T38954 | 134-141 | SO:0000704 | denotes | genetic |
| T73828 | 160-166 | UBERON:0002405;GO:0006955 | denotes | immune |
| T2948 | 167-175 | GO:0006955 | denotes | response |
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 274 | 176-188 | Disease | denotes | inflammation | MESH:D007249 |
LitCovid-PD-FMA-UBERON
| Id | Subject | Object | Predicate | Lexical cue | fma_id |
|---|---|---|---|---|---|
| T74 | 95-100 | Body_part | denotes | cells | http://purl.org/sig/ont/fma/fma68646 |
LitCovid-PD-MONDO
| Id | Subject | Object | Predicate | Lexical cue | mondo_id |
|---|---|---|---|---|---|
| T81 | 176-188 | Disease | denotes | inflammation | http://purl.obolibrary.org/obo/MONDO_0021166 |
LitCovid-PD-CLO
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T116 | 79-84 | http://purl.obolibrary.org/obo/NCBITaxon_10239 | denotes | virus |
| T117 | 95-100 | http://purl.obolibrary.org/obo/GO_0005623 | denotes | cells |
LitCovid-PD-GO-BP
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T17 | 160-175 | http://purl.obolibrary.org/obo/GO_0006955 | denotes | immune response |
| T18 | 176-188 | http://purl.obolibrary.org/obo/GO_0006954 | denotes | inflammation |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T64 | 0-189 | Sentence | denotes | These therapies generally target the following processes: (1) the entry of the virus into host cells, (2) multiplication of the viral genetic material, and (3) immune response/inflammation. |